Cell cycle-related gene abnormalities and product expression in esophageal carcinoma

Laboratory Investigation

Volumn 78, Issue 9, 1998, Pages 1049-1057

  Roncalli, Massimo ^a,b   Bosari, Silvano ^b   Marchetti, Antonio ^c   Buttitta, Fiamma ^c   Bossi, Paola ^a   Graziani, Daniela ^b   Peracchia, Alberto ^d   Bonavina, Luigi ^d   Viale, Giuseppe ^b   Coggi, Guido ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GENE PRODUCT; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE; DNA METHYLATION; ESOPHAGUS CARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

CARCINOMA; CELL CYCLE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ESOPHAGEAL NEOPLASMS; GENE AMPLIFICATION; GENE EXPRESSION; GENES, RETINOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; METHYLATION; MUTATION; RETINOBLASTOMA PROTEIN;

EID: 0031660965     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Adelaide J, Monges G, Derderian C, Seitz JF, and Birnbaum D (1995). Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 71:64-68.
2. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, and Wennerberg JP (1997). Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:380-389.
3. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, and Bartek J (1995a). Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55:949-956.
4. Bartkova J, Lukas J, Strauss M, and Bartek J (1994). Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 172:237-245.
5. Bartkova J, Lukas J, Strauss M, and Bartek J (1995b). Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778.
6. Behars OH, Henson DE, Hutter RVP, and Kennedy BJ (1992). Manual for staging of cancer. Philadelphia: JB Lippincott.
7. Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M, Bevilacqua G, and Coggi G (1995). Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis: A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4:249-255.
8. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, and de la Chapelle A (1996). Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56:3331-3337.
9. Cawkwell L, Lewis FA, and Quirke P (1994). Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 70:813-818.
10. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, and Peracchia A (1997). p53 protein accumulation and p53 gene mutation in esophageal carcinoma: A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79:425-432.
11. Cordon-Cardo C (1995). Mutations of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol 147:545-560.
12. Esteve A, Martel-Planche G, Sylla BS, Hollstein M, Hainaut P, and Montesano R (1996). Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer 66:301-304.
13. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, and Livingston DM (1993). Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73: 487-497.
14. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, and Beger HG (1997). Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57:1634-1637.
15. Geradts J, Kratzke RA, Niehans GA, and Lincoln CE (1995). Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/ MTS1) product p16INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011.
16. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, and Jones PA (1995). Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
17. Gramlich TL, Fritsch CR, Maurer D, Eberle M, and Gansler TS (1994). Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 3:255-259.
18. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
19. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, McDaniel T, Boynton RF, and Zou ZQ (1993). Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 53:1889-1894.
20. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, and Dracopoli NC (1994). Germline p16 mutations in familial melanoma (see comments). Nat Genet 8:15-21.
21. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, and Terada M (1995). Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 55:3421-3423.
22. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez-Beato M, Soler F, Perez-Losada A, Nayach I, Mallofre C, Piris MA, Montserrat E, and Cardesa A (1996). Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas: Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 148: 1591-1600.
23. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, and Weinstein IB (1993). Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90:9026-9030.
24. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, and Geradts J (1996). Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 56:3415-3420.
25. Li Y, Nichols MA, Shay JW, and Xiong Y (1994). Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54:6078-6082.
26. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC, and Huang DP (1996). Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721-2725.
27. Lukas J, Bartkova J, Rohde M, Strauss M, and Bartek J (1995). Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15:2600-2611.
28. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL, and Fodstad O (1996). Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-916.
29. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti CA, and Bevilacqua G (1997). Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol 181:178-182.
30. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, and Sidransky D (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers (see comments). Nat Med 1:686-692.
31. Montesano R, Hollstein M, and Hainaut P (1996). Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review. Int J Cancer 69:225-235.
32. Mori T, Miura K, Aoki T, Nishihira T, Mori S, and Nakamura Y (1994). Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397.
33. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, and Harris CC (1995). Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451.
34. Otterson GA, Kratzke RA, Coxon A, Kim YW, and Kaye FJ (1994). Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375-3378.
35. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, and Sidransky D (1996). High frequency of p16 (CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633.
36. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular cloning: A laboratory manual. New York: Cold Spring Harbor.
37. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG, Abraham JM, Krasna MJ, Cottrell J, and Meltzer SJ (1994). Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 54:6094-6096.
38. Wakabayashi M, Shiro T, Seki T, Nakagawa T, Itoh T, Imamura M, Shiozaki Y, Inoue K, and Okamura A (1995). Lewis Y antigen expression in hepatocellular carcinoma: An immunohistochemical study. Cancer 75:2827-2835.
39. Worsley SD, Jennings BA, Khalil KH, Mole M, and Girling AC (1996). Cyclin D1 amplification and expression in human breast carcinoma: Correlation with histological prognostic markers and oestrogen receptor expression. J Clin Pathol: Mol Pathol 49:M46-M50.
40. Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM, and Meltzer SJ (1994). The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9:3737-3741.